Aim and Scope

The Emerging Cancers is an international, peer-reviewed, open-access journal dedicated to publishing high-quality research across all aspects of oncology. As a non-profit publication, it aims to advance cancer research, diagnosis, and treatment by offering a platform for oncologists, cancer biologists, and clinical researchers to share their findings and innovations.

This journal encompasses a wide range of subjects related to cancer research and oncology. Areas of interest include, but are not limited to:

Cancer Biology and Molecular Oncology: This includes tumour biology, oncogenes, tumour suppressors, cancer genetics, epigenetics, cancer stem cells, and mechanisms of metastasis.

Clinical Oncology: Topics include medical oncology, surgical oncology, radiation therapy, palliative care, cancer screening, staging, and multidisciplinary cancer management.

Cancer Immunology and Immunotherapy: This encompasses checkpoint inhibitors, CAR-T cell therapy, tumour microenvironment, immune evasion, and cancer vaccines.

Cancer Diagnostics and Biomarkers: Areas covered include liquid biopsy, molecular diagnostics, imaging in oncology, pathology, tumour markers, and early detection strategies.

Drug Development and Targeted Therapy: This section covers chemotherapy, targeted agents, drug resistance, pharmacogenomics, clinical trials, and precision oncology.

Conflict of Interest

All authors, reviewers, and editors are required to disclose any potential conflicts of interest related to their submission or participation in the review process. Conflicts of interest may include financial, professional, or personal relationships that could influence the outcome of the work.

Open Access Policy

The Emerging Cancers is committed to an Open Access publishing model, ensuring that all articles are freely accessible to the public. Published under a Creative Commons Attribution License (CC BY), our policy allows for unrestricted use and distribution with appropriate attribution to the authors.  Authors retain copyright of their work, and  Article Processing Charges (APCs) incurred support the journal's operations while maintaining rigorous peer review and publication standards.

Copyright and Licensing

When submitting an article, authors are required to agree to an open access Creative Commons (CC BY 4.0) license. This license allows authors to retain copyright of their work while granting users the right to download, print, reuse, share, and distribute the article, provided that proper credit is given to the authors and the original source. This ensures maximum visibility and availability of the article, allowing it to be included in scientific archives. Consistent with open access principles, the journal makes all article abstracts and full-text PDFs freely accessible to the public upon publication.

Digital archiving policy

This journal utilizes the PKP Preservation Network, Global LOCKSS Network, and Portico to establish a distributed archiving system across participating libraries. These networks enable libraries to maintain permanent archives of the journal, ensuring its long-term preservation and restoration capabilities.

Plagiarism policy

The Emerging Cancers is committed to maintaining the highest standards of integrity and academic ethics. We have a zero-tolerance policy towards plagiarism in all its forms. All submitted manuscripts are screened for plagiarism using advanced detection tools (Turnitin and iThenticate). Any form of plagiarism, including direct copying, paraphrasing without proper attribution, or self-plagiarism, is prohibited. If detected before publication, the manuscript will be rejected. If discovered after publication, the journal will retract or correct the article and notify readers of the misconduct. Authors are responsible for ensuring that their work is original, properly cited, and does not infringe on the intellectual property of others.

Publishing Ethics

When submitting studies involving human participants, authors must follow ICMJE recommendations on privacy and informed consent. Identifiable patient data such as descriptions, photos, or genetic information can only be published with written informed consent, which requires showing the patient the manuscript prior to publication. If the patient is deceased, consent must be obtained from the family or estate. Authors must secure this consent and keep records but do not need to submit them to the journal. Consent should specify that the manuscript may be published online, in print, and shared via social media.

For animal studies, authors must confirm that the animals were cared for according to institutional or national standards. All experiments should comply with relevant guidelines, and procedures must minimize harm to the animals, with anesthetics and analgesics clearly described.

Approval from an ethics committee is required for all clinical and animal studies. Researchers are encouraged to register clinical trials in public databases, such as clinicaltrials.gov, with the trial number and detailed methods included in the manuscript.

Emerging Cancers

Full title: Emerging Cancers

ISSN: 3023-3488 (online)

Publisher: Emerging Publishing Society